Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 9—September 2016
CME ACTIVITY - Research

Fluoroquinolone-Resistant and Extended-Spectrum β-Lactamase–Producing Escherichia coli Infections in Patients with Pyelonephritis, United States1

David A. TalanComments to Author , Sukhjit S. Takhar, Anusha Krishnadasan, Fredrick M. Abrahamian, William R. Mower, Gregory J. Moran, and EMERGEncy ID Net Study Group
Author affiliations: David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Los Angeles, California, USA (D.A. Talan, A. Krishnadasan, F.M. Abrahamian, W.R. Mower, G.J. Moran); Olive View–UCLA Medical Center, Los Angeles (D.A. Talan, A. Krishnadasan, F.M. Abrahamian, G.J. Moran); Brigham and Women’s Hospital, Boston, Massachusetts, USA (S.S. Takhar); Harvard Medical School, Boston (S.S. Takhar); Ronald Reagan Medical Center, Los Angeles (W.R. Mower)

Main Article

Table 3

Antimicrobial drug resistance rates for Escherichia coli isolates from US emergency department patients with acute uncomplicated and complicated pyelonephritis, July 2013–December 2014*

Antimicrobial drug Patients with antimicrobial drug–resistant isolates, no./no. tested (%)
Total, N = 453 Uncomplicated cases, N = 272 Complicated cases, N = 181
Trimethoprim/sulfamethoxazole 165/453 (36.4) 111/272 (40.8) 54/181 (29.8)
Ampicillin 259/453 (57.2) 152/272 (55.9) 107/181 (59.1)
Cefazolin 52/367 (14.2) 18/219 (8.2) 34/148 (23.0)
Ceftriaxone 35/453 (7.7) 7/272 (2.6) 28/181 (15.5)
Ciprofloxacin 48/397 (12.1) 15/237 (6.3) 33/160 (20.6)
Levofloxacin 33/325 (10.2) 10/195 (5.1) 23/130 (17.7)
Gentamicin 43/436 (9.9) 19/261 (7.3) 24/175 (13.7)
Imipenem 0/135 (0) 0/90 (0) 0/45 (0)
Ertapenem 0/201 (0) 0/111 (0) 0/90 (0)
Meropenem 0/161 (0) 0/96 (0) 0/65 (0)
Doripenem 0/139 (0) 0/74 (0) 0/65 (0)

*Denominators indicate number of isolates tested against a specific antimicrobial drug; the composition of testing panels varied by site.

Main Article

1Preliminary results of this research were presented at the 2014 IDWeek Meeting, Philadelphia, PA, USA, October 8–12, 2014.

Page created: August 11, 2016
Page updated: August 11, 2016
Page reviewed: August 11, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external